Go Pro
NASDAQ:OPRX

OptimizeRx (OPRX) Stock Price, News & Analysis

OptimizeRx logo
$6.74 -0.19 (-2.74%)
Closing price 04:00 PM Eastern
Extended Trading
$6.78 +0.04 (+0.59%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About OptimizeRx Stock (NASDAQ:OPRX)

Advanced

Key Stats

Today's Range
$6.67
$6.90
50-Day Range
$4.54
$6.93
52-Week Range
$4.54
$22.25
Volume
100,063 shs
Average Volume
223,259 shs
Market Capitalization
$126.44 million
P/E Ratio
19.26
Dividend Yield
N/A
Price Target
$13.43
Consensus Rating
Moderate Buy

Company Overview

OptimizeRx, Inc. is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations. These tools allow pharmaceutical and biotechnology firms to deliver personalized messaging to physicians and care teams, ensuring that relevant formulary and financial support information is accessible at the moment of treatment. In addition, OptimizeRx provides data analytics and reporting capabilities that enable clients to measure the impact of their digital outreach and refine strategies to drive prescription growth and patient outcomes.

Founded in 2003 and headquartered in Cleveland, Ohio, OptimizeRx has formed partnerships with a broad spectrum of EHR vendors and health systems across the United States. The company’s network reaches tens of thousands of healthcare providers, making it one of the largest point-of-care communication platforms in the country. OptimizeRx collaborates closely with payers to integrate eligibility and benefit information, ensuring that savings offers and coverage details are accurate and up to date.

OptimizeRx is led by Chief Executive Officer David Whitlinger, who joined the company in 2019 and has overseen its expansion of digital service offerings and strategic alliances. Under his leadership, the company has focused on enhancing interoperability, scaling its network footprint and delivering advanced analytics to clients. While its primary market remains the U.S., OptimizeRx continues to explore opportunities to extend its digital health network into new regions and therapeutic areas.

AI Generated. May Contain Errors.

OptimizeRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

OPRX MarketRank™: 

OptimizeRx scored higher than 91% of companies evaluated by MarketBeat, and ranked 75th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    OptimizeRx has a consensus price target of $13.43, representing about 99.2% upside from its current price of $6.74.

  • Amount of Analyst Coverage

    OptimizeRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about OptimizeRx's stock forecast and price target.
  • Earnings Growth

    Earnings for OptimizeRx are expected to grow by 17.65% in the coming year, from $0.51 to $0.60 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OptimizeRx is 19.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.39.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OptimizeRx is 19.26, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 270.82.

  • Price to Book Value per Share Ratio

    OptimizeRx has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about OptimizeRx's valuation and earnings.
  • Percentage of Shares Shorted

    8.41% of the float of OptimizeRx has been sold short.
  • Short Interest Ratio / Days to Cover

    OptimizeRx has a short interest ratio ("days to cover") of 4.21.
  • Change versus previous month

    Short interest in OptimizeRx has recently increased by 29.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    OptimizeRx does not currently pay a dividend.

  • Dividend Growth

    OptimizeRx does not have a long track record of dividend growth.

  • News Sentiment

    OptimizeRx has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for OptimizeRx this week, compared to 2 articles on an average week.
  • Search Interest

    10 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OptimizeRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.50% of the stock of OptimizeRx is held by insiders.

  • Percentage Held by Institutions

    76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OptimizeRx's insider trading history.
Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OPRX Stock News Headlines

Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Price Target at $13.43
Elon's next move will be bigger than the IPO – and it could happen any day now
Hedge fund legend Larry Benedict - who delivered a 279% return on cash in 2025 and went on a 20-year winning streak - says the SpaceX IPO wasn't the main event. It was the trigger. He's identified what he calls the 'Final Phase of Elon's Master Plan,' and one specific ticker he believes could see billions forced into it within days. It's not SpaceX, Tesla, or any company you'd associate with Elon Musk. Larry is revealing the ticker free today.tc pixel
See More Headlines

OPRX Stock Analysis - Frequently Asked Questions

OptimizeRx's stock was trading at $12.26 on January 1st, 2026. Since then, OPRX stock has decreased by 45.0% and is now trading at $6.74.

OptimizeRx Corp. (NASDAQ:OPRX) released its quarterly earnings results on Tuesday, May, 12th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.01 by $0.13. The firm had revenue of $19.84 million for the quarter, compared to analysts' expectations of $18.74 million. OptimizeRx had a net margin of 6.37% and a trailing twelve-month return on equity of 10.86%.
Read the conference call transcript
.

OptimizeRx's board approved a stock buyback program on Thursday, March 5th 2026, which allows the company to buy back $10,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's leadership believes its stock is undervalued.

OptimizeRx's top institutional shareholders include Bank of New York Mellon Corp (0.34%). Insiders that own company stock include William J Febbo, James Paul Lang, Stephen L Silvestro, Edward Stelmakh, Patrick D Spangler and Marion Odence-Ford.
View institutional ownership trends
.

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/12/2026
Today
8/06/2026
Next Earnings (Estimated)
8/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Technology
Sub-Industry
Healthcare Technology
Current Symbol
NASDAQ:OPRX
CIK
1448431
Employees
100
Year Founded
2006

Price Target and Rating

High Price Target
$24.00
Low Price Target
$7.00
Potential Upside/Downside
+99.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.35
Trailing P/E Ratio
19.26
Forward P/E Ratio
13.22
P/E Growth
N/A
Net Income
$5.13 million
Net Margins
6.37%
Pretax Margin
8.92%
Return on Equity
10.86%
Return on Assets
7.93%

Debt

Debt-to-Equity Ratio
0.16
Current Ratio
5.37
Quick Ratio
5.37

Sales & Book Value

Annual Sales
$109.43 million
Price / Sales
1.16
Cash Flow
$0.96 per share
Price / Cash Flow
7.04
Book Value
$6.88 per share
Price / Book
0.98

Miscellaneous

Outstanding Shares
18,760,000
Free Float
17,358,000
Market Cap
$126.44 million
Optionable
Optionable
Beta
1.08

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:OPRX) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners